Chronic cutaneous lupus erythematosus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:03:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chronic cutaneous lupus erythematosus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-litifilimab-for-patients-with-active-subacute-or-chronic-cutaneous-lupus-erythematosus-resistant-to-antimalarial-therapy/ Wed, 29 Apr 2026 14:47:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-litifilimab-for-patients-with-active-subacute-or-chronic-cutaneous-lupus-erythematosus-resistant-to-antimalarial-therapy/ This clinical trial is focused on studying two types of lupus that affect the skin: Subacute Cutaneous Lupus Erythematosus and Chronic Cutaneous Lupus Erythematosus. These conditions can cause rashes and lesions on the skin, and sometimes they may also involve other parts of the body. The study is testing a new treatment called BIIB059, which is given as an injection. The purpose of the study is to evaluate how effective and safe BIIB059 is in reducing the activity of skin disease in people who have these types of lupus and have not responded well to antimalarial treatments.

Participants in the study will receive either the BIIB059 injection or a placebo, which looks like the treatment but does not contain the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over a period of time, with regular check-ups to monitor the participants’ health and the effects of the treatment.

The trial is divided into two parts, and participants will be assessed using specific scores that measure the severity and activity of their skin condition. These scores help researchers understand how well the treatment is working. The study aims to provide valuable information about the potential benefits of BIIB059 for people with these challenging skin conditions. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

]]> Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus https://clinicaltrials.eu/trial/study-on-the-effects-of-daxdilimab-for-adults-with-moderate-to-severe-discoid-lupus-erythematosus/ Wed, 29 Apr 2026 14:28:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-daxdilimab-for-adults-with-moderate-to-severe-discoid-lupus-erythematosus/ This clinical trial focuses on evaluating a new treatment for Primary Discoid Lupus Erythematosus (DLE), a skin condition that causes disc-shaped patches on the skin. The study will test a medication called daxdilimab, which is given as an injection under the skin, compared to placebo in people with moderate to severe forms of the disease.

The purpose of this study is to determine if daxdilimab can reduce disease activity in adults with DLE after 24 weeks of treatment. During the study, participants will receive either daxdilimab or placebo through subcutaneous injections. Some participants may continue their current medications such as antimalarials, methotrexate, mycophenolate, azathioprine, or low-dose corticosteroids if they were already taking them before the study.

The study will monitor changes in the skin lesions and overall disease activity throughout the treatment period. The medication dose will not exceed 300 milligrams. The researchers will also check how the body processes the medication and watch for any side effects that may occur during the treatment period.

]]> Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE) https://clinicaltrials.eu/trial/study-on-enpatoran-for-patients-with-systemic-lupus-erythematosus-and-cutaneous-lupus-erythematosus/ Wed, 29 Apr 2026 14:28:33 +0000 https://clinicaltrials.eu/trial/study-on-enpatoran-for-patients-with-systemic-lupus-erythematosus-and-cutaneous-lupus-erythematosus/ This clinical study focuses on Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE), which are autoimmune conditions where the body’s immune system attacks its own tissues. SLE can affect multiple organs throughout the body, while CLE primarily affects the skin, causing rashes and lesions. The study will test a new medication called enpatoran in patients who are already receiving standard treatments for lupus.

The purpose of this research is to evaluate how different doses of enpatoran work in reducing disease activity, particularly focusing on skin symptoms and overall disease control. During the study, participants will receive either enpatoran tablets or placebo in addition to their current lupus medications. The study will track changes in participants’ symptoms and overall health for up to 24 months.

This is a Phase 2 study, which means the medication has already been tested for basic safety in humans, and researchers are now studying how well it works at different doses. The study is designed to be double-blind, which means neither the participants nor the healthcare providers will know who is receiving enpatoran or placebo during the study period.

]]> Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy https://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-litifilimab-for-adults-with-active-subacute-or-chronic-cutaneous-lupus-erythematosus-resistant-to-antimalarial-therapy/ Wed, 29 Apr 2026 14:25:39 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-litifilimab-for-adults-with-active-subacute-or-chronic-cutaneous-lupus-erythematosus-resistant-to-antimalarial-therapy/ This clinical trial is focused on studying two types of skin conditions related to lupus: Subacute Cutaneous Lupus Erythematosus and Chronic Cutaneous Lupus Erythematosus. These conditions can cause skin rashes and lesions, and sometimes they may be associated with other symptoms throughout the body. The study is testing a treatment called BIIB059, also known as litifilimab, which is given as an injection under the skin. The purpose of the study is to evaluate the long-term safety and effectiveness of this treatment in adults who have these active skin conditions and have not responded well to or cannot tolerate antimalarial medications.

Participants in the study will receive the BIIB059 treatment over a period of time, and their health will be monitored to see how they respond to the medication. The study will look at how well the treatment works in reducing the severity of the skin conditions and any potential side effects that may occur. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The study will last for up to 128 weeks, during which participants will have regular check-ups to assess their condition and any changes in their symptoms. The goal is to gather information on how safe and effective BIIB059 is for treating these types of lupus-related skin conditions over a long period. This information will help determine if the treatment can be a viable option for people with these conditions in the future.

]]> Study on the Safety and Effectiveness of Deucravacitinib for Patients with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-deucravacitinib-for-patients-with-active-discoid-and-or-subacute-cutaneous-lupus-erythematosus/ Wed, 29 Apr 2026 14:23:27 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-deucravacitinib-for-patients-with-active-discoid-and-or-subacute-cutaneous-lupus-erythematosus/ This clinical trial is focused on studying the effects of a medication called deucravacitinib on individuals with a skin condition known as Discoid Lupus Erythematosus (DLE) and/or Subacute Cutaneous Lupus Erythematosus (SCLE). These are types of lupus that primarily affect the skin, causing rashes and lesions. The medication being tested is a film-coated tablet taken orally, and it is being evaluated in two different doses: 3 mg and 6 mg, both taken twice a day. The study also includes a comparison with a placebo to assess the medication’s effectiveness and safety.

The purpose of the study is to evaluate how well deucravacitinib works in reducing the severity of skin symptoms in participants with active DLE and/or SCLE. Participants will be randomly assigned to receive either the medication or a placebo. The study will last for a period of up to 52 weeks, during which participants will have regular check-ups to monitor their condition and any changes in their symptoms. The main focus will be on the change in the severity of skin symptoms at Week 16, as measured by a specific scoring system used to assess skin disease activity.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. The study aims to provide valuable information on the potential benefits and risks of using deucravacitinib for treating these specific types of lupus. This research could contribute to better understanding and management of DLE and SCLE, potentially offering new treatment options for those affected by these conditions.

]]>